Meeting Banner
Abstract #1077

3T MRI and MR Spectroscopy of an Ovine Model of Tay-Sachs Disease After AAV-Mediated Gene Therapy

Heather L. Gray-Edwards1, Nouha Salibi2, Diane Wilson1, Ashley Randle1, Ronald J. Beyers3, Thomas Stewart Denney3, Ravi T. Seethamraju2, Shumin Wang3, Xiaotong Sun3, Allison M. Bradbury4, Victoria J. McCurdy4, Nancy Cox1, Douglas R. Martin4

1Scott-Ritchey Research Center, Auburn University, Auburn, Al, United States; 2MR R&D, Siemens Healthcare, Malvern, PA, United States; 3Department of Electrical and Computer Engineering, Auburn Univeristy, Auburn, AL, United States; 4Anatomy, Physiology and Pharmacology, Auburn University, Auburn, Al, United States

Tay-Sachs Disease (TSD) is a form of GM2 gangliosidosis in humans that is untreatable and fatal by 5 years of age. The ovine TSD model has the same subunit mutation as Tay-Sachs patients. AAV2/rh8 vectors expressing ovine hexosaminidase subunits were injected in the lateral ventricle and bilaterally into the thalamus of TSD sheep. MR images and Magnetic Resonance Spectroscopy (MRS) data were acquired on a 3 Tesla MAGNETOM Verio scanner. Untreated TSD sheep show gray:white matter isointensity and elevations of brain metabolites. Gene replacement in the ovine TSD model results in restoration of both brain architecture and metabolites.

Abstract PDF

Keywords

abstract activity amelioration analyzed anatomical anatomy animals architecture array auburn audience authentic axial benefit bilaterally body brain brains caused channel chart chemical chess children choline clinical coil computer consistent coronal cortex cortical decreased deficient defined determination develop disease diseases distribution electrical endpoint engineering enzyme express external fatal form future gene global gradient gray heather human humane humans hyper in vivo individual injection integrals intense intensities interface intermediate invaluable invasive isotropic just lateral located magnetization magnitude martin mediated merge metabolite metabolites model months mutation normalization normalized opportunities outlined parietal patients peak phantom pharmacology physiology placed placement planned prepared preservation press prior progression quantification radiology rapid replacement resolution resolved respectively scanner scheduled selective sheep software solution spectroscopy start storage structures studies subunit subunits support suppression target thalamus therapy throughout treated trials untreated user variations vector ventricle versus water white years